Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoADAURA neoadjuvant osimertinib with or without chemotherapy versus standard chemotherapy in resectable EGFR-mutant NSCLC
CTR20212143Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jun 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212143.